Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2 Study of the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Epetraborole Tablets for the Treatment of Adults With Phlebotomy-Dependent Polycythemia Vera

NCT07891533 is registered in ClinicalTrials.gov with AN2 Therapeutics, Inc as lead sponsor.

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, 14-day trial. Card required. Your first charge is when the trial ends. See pricing

Get the NCT07891533 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Follow this trial by email

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2 Study of the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Oral Epetraborole Tablets for the Treatment of Adults With Phlebotomy-Dependent Polycythemia Vera
Lead sponsor
AN2 Therapeutics, Inc
Phase
Phase 2
Overall status
Not yet recruiting
Start date
November 30, 2026
Completion date
June 30, 2030
Enrollment
75 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

polycythemia vera (snomed ct: 109992005)

Arms

As registered; 5 arms.

  • Sentinel Cohort ExperimentalEpetraborole

    Open Label Fixed Dose Epetraborole

  • Part 1: Dose Selection Cohort ExperimentalEpetraborole

    Open Label Epetraborole Dose Selection

  • Part 2: Epetraborole (Double Blind) ExperimentalEpetraborole

    Fixed Dose Epetraborole

  • Part 2: Placebo (Double Blind Randomized Withdrawal) Placebo comparatorPlacebo

    Placebo Control

  • Part 3: Open Label Extension Cohort (Optional) ExperimentalEpetraborole

    Open Label Epetraborole

Primary endpoints

Registered primary outcome measures; 1 primary.

  • Part 2: Proportion of Participants per Treatment Group Maintaining Clinical Success defined as hematocrit control, not undergoing therapeutic phlebotomy and completing 12 weeks of treatment in Part 2 Week 29 - Week 40

Lead sponsor's other trials

AN2 Therapeutics, Inc, most recent start first.

Similar trials

Same condition (Polycythemia Vera) and phase, most recent start first.